{"DataElement":{"publicId":"3304814","version":"1","preferredName":"Salvage Therapy Anti-PD-1 Monoclonal Antibody Administer Specify","preferredDefinition":"the free-text field to specify the type of salvage therapy, treatment that is given after the cancer has not responded to other treatments, using a humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.","longName":"3304810v1.0:2018810v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3304810","version":"1","preferredName":"Salvage Therapy Anti-PD-1 Monoclonal Antibody Administer","preferredDefinition":"information related to the salvage therapy, treatment that is given after the cancer has not responded to other treatments, using a humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.","longName":"2177011v1.0:3304808v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177011","version":"1","preferredName":"Salvage Therapy","preferredDefinition":"Treatment that is given after the cancer has not responded to other treatments.","longName":"Salvage Therapy","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Salvage Therapy","conceptCode":"C15359","definition":"Performing a salvage procedure is the last resort. The clinical situation involves either ongoing life support measures, life support measures for more than 60 seconds during the prior 10 minutes, or unanticipated institution of extracorporeal circulatory support. (ACC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AD8-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3304808","version":"1","preferredName":"Anti-PD-1 Monoclonal Antibody CT-011 Administer","preferredDefinition":"A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Anti-PD-1 monoclonal antibody CT-011 blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.:To dispense, apply, or tender something to another, such as administering a medicine.","longName":"C71014:C64912","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pidilizumab","conceptCode":"C71014","definition":"A humanized monoclonal antibody directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. Pidilizumab blocks interaction between the receptor PD-1 with its ligands, PD-1 ligand 1 (PD-1L1) and PD-1 ligand 2 (PD-1L2), resulting in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells, and the augmentation of the anti-tumor activities of NK cells. PD-1 is an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells; its ligands, PD-1L1 and PD-1L2, are expressed not only by hematopoietic cells but also by cells in non-lymphoid tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administer","conceptCode":"C64912","definition":"To dispense, apply, or tender something to another, such as administering a medicine.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1E102A3-9589-BD84-E040-BB89AD432297","latestVersionIndicator":"Yes","beginDate":"2011-11-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-16","modifiedBy":"ONEDATA","dateModified":"2011-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1E102A3-959A-BD84-E040-BB89AD432297","latestVersionIndicator":"Yes","beginDate":"2011-11-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018810","version":"1","preferredName":"Therapies Specify","preferredDefinition":"the free text field related to therapy.","longName":"TX_SPEC","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184338","version":"1","preferredName":"Specify","preferredDefinition":"Specify; be specific about something; define clearly.","longName":"Specify","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-2084-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BA236E-6B3E-350B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-03-25","modifiedBy":"CAMPBELB","dateModified":"2008-03-28","changeDescription":"released as entered during ISO compliance update","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"Anti-PD1 antibody, specify","type":"Preferred Question Text","description":"Anti-PD1 antibody, specify","url":null,"context":"CTEP"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Anti-PD1, specify","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1E102A3-95D3-BD84-E040-BB89AD432297","latestVersionIndicator":"Yes","beginDate":"2011-11-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-16","modifiedBy":"ROUILLAS","dateModified":"2014-11-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}